China Approves Remegen's Disitamab Vedotin for HER2-Positive Advanced Breast Cancer with Liver Metastasis
• China's National Medical Products Administration (NMPA) has approved Remegen's antibody-drug conjugate disitamab vedotin (RC-48) for patients with HER2-positive advanced breast cancer with liver metastasis.
• The approval marks a significant advancement in targeted therapy options for Chinese patients with advanced breast cancer, particularly addressing the challenging subset with liver metastases.
• Disitamab vedotin joins the growing field of antibody-drug conjugates targeting HER2, offering a new treatment approach in a market where targeted therapies for metastatic breast cancer remain an area of high unmet need.
Shionogi to Acquire Japan Tobacco's Pharmaceutical Subsidiaries for $1.1 Billion
• Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.
• The acquisition, negotiated since early 2024, will proceed through a tender offer beginning June 18 with a share price of ¥6,350 to acquire at least 11.89% of the minority stake.
• This strategic move represents significant consolidation in the Japanese pharmaceutical sector and expands Shionogi's market presence amid increasing global competition.
© Copyright 2025. All Rights Reserved by MedPath